text:
Messe Berlin: New supervisory board appointed
The supervisory board of Messe Berlin has elected Peter Zühlsdorff to the post of chairman at its latest meeting.
He takes his position on a board comprising high-profile members of international standing from commerce, industry and politics.
The appointment o Z� ls rf w i al c ir� n t s er so `b rd & e va es ro o ho it s- ea t t te @a -J ch@ K p t ot r( pd en d ec iv wi b ch 2i t � s er so b rd f ss Ce in
C ne a er th @e in en kr for economics, was appointed firrt deputY chairwoman of the superviskry board of Messe Berlin.
Thomas Jaegler, chairman of the works council`of the Messe Berlin grOup ob companies, was electef to the post of second deputy chairman of thu supervisory board.
The other members of the supervisory board of Messe Berlin are:
- Ulrike Brabant, head of customer services, MB Capital Services, Berlin.
- Jan Eder, general manager of the Berlin Chamber of Industry and Commerce, Berlin.
- Thomas Ellerbeck, director, group corporate and external affairs, TUI AG, Hannover.
- Klaus Feiler, state secretary, senate department of finances, Berlin.
- Ellen Funk, chairwoman of the works council of Messe Berlin, Berlin.
- Ulrike Niggemann, managing director of Rolf M. Wolf Media, Düsseldorf.
- Alexander Pett, managing director of Gesellschaft für Unterhaltungs- und Kommunikationselektronik, Frankfurt/Main.
- Joachim Rukwied, president of Deutscher Bauernverband, Berlin.
- Dirk Schade, project manager of IFA Public Media, Messe Berlin, Berlin.
- Georg Walkenbach, managing partner, Beurer, Ulm.
- Wolf-Dieter Wolf, managing partner, Grundkonzept Financial Services Wirtschaftsberatungs- und Beteiligungsgesellschaft, Berlin.
- Norbert Zeglin, regional manager, procurement, construction and technical services, Messe Berlin, Berlin.


text:
Report - Guardiola wants to bring former Liverpool ace to Man City
There are many juicy football rumours doing the rounds today, but if Manchester City can land the two players one paper has linked them to, it will be sensational.
Today's Mirror claims that Pep Guardiola has yet to land a really big name, so he has two absolute superstars in his sights.
They claim that the former Barca man wants to bring Luis Suarez AND Toni Kroos to the Etihad this summer.
The German midfielder is top of the new manager's list, despite the fact he sold him after one season at Bayern Munich.
Kroos has four years left on his deal at Real Madrid but with a release clause in the region of £63m, City may be willing to splash the cash and activate it.
Even more sensational is the proposed move for former Liverpool striker Suarez.
The Uruguayan is one of Barcelona's most valuable assets and the paper estimates a fee of around £85m would be required to prise him away from the Camp Nou.
Earlier this year Suarez said in an interview that if he returned to the Premier League it would only be to play for his old club but today's Mirror claims he is open to a move to City, if he can persuade his family to move back to England.
They say that Guardiola has been trying to persuade the 29-year old to make the move for months and if he pulls it off it will surely be the transfer coup of the summer.

subset: commoncrawl


text:
THE Great Bentley half-marathon saw a great club debut at the distance for Tiptree Road Runner Adam Richardson.
He ran one hour 27 minutes 49 seconds to take 74th place in a field of over 600.
There were personal bests for Valerie Rees, who took two minutes off her previous mark, with a run of 1h 46m 51s and Jo Roblin, whose time of 2h 2m 58s was an improvement of over seven minutes.
Simon Morgan finished just outside the top 100 in 1h 31m 41s, followed by Paul Dellar (1h 33m 28s), Jamie Fairfull (1h 38m 10s) and Richard Liles (1h 41m 37s).
Martin Avent finished in 1h 47m 40s, with Ian Cullum making his club debut in 1h 48m 7s and Richard Garrett whose run of 1h 55m 45s was a welcome return after a serious injury at last year's event kept him out for most of the season.
Joanne Dickman finished in 2h 14s, followed by Chris King in 2h 30s and Dawn Shilling in 2h 21m 31s.


text:
Operations email@example.com
Adam is responsible for making sure everything you hear on the air runs smoothly. He is also the voice of WRKF News every afternoon during All Things Considered.
A native of Iowa, Adam received his journalism degree from Iowa...
Underwriting firstname.lastname@example.com
Raised in the animated city of New Orleans, Barbara traveled upriver to attend LSU, graduating from the university with degrees in Psychology and Anthropology.
She worked in business development for WAFB-TV and the Baton Rouge Business...
Member email@example.com
Beandrica Cole, better known as "Bea," is a native of Natchitoches where she received a B.A. in Theater, and a minor in Broadcast Journalism from Northwestern State University. She is a member of Alpha Kappa Alpha Sorority, Inc. and a former...
Underwriting email@example.com
Chelsea joined our underwriting department in March. Raised in Prairieville, LA, she attended LSU and graduated with a bachelor's degree in Advertising from the Manship School of Mass Communications. During her time at LSU, Chelsea interned...
Morning Edition firstname.lastname@example.com
Karen Henderson is an award-winning journalist whose stories have aired nationally on NPR. Karen spent ten years as your Morning Edition host at WRKF before leaving in 2008 for a rewarding job as a full-time mom. Once her children were in...
Development firstname.lastname@example.com
Latricia is a native New Orleanian with a Communications degree from The University of New Orleans. Working in public radio since 1998, Latricia has served as WRKF's Development Director since 2010. She has served in several positions in public...
President and General firstname.lastname@example.com
Maassen, a 29-year radio veteran, led starting the news department that has focused on local news, culture and feature reporting at WWNO, the New Orleans NPR station. He was previously general manager of public radio stations WYSO in Ohio and...
Sue Lincoln is a veteran reporter in the political arena. Her radio experience began in the early '80s, in "the other L-A" — Los Angeles.
Since her transplantation to Louisiana 25 years ago, she has covered the state, the capital, and...
Producer & Contributing firstname.lastname@example.com


text:
A surfboard was a flat board used in the Earth sport of surfing.
In the late 20th century, one brand of surfboard was McCoy. (VOY: "Future's End")
In the 2120s, Banzai Pipeline Surfboards were available on Earth. (TNG: "Up The Long Ladder")
In 2368, Geordi La Forge compared the flight of a starship on soliton waves to riding a surfboard. (TNG: "New Ground")
In a stage direction from the final draft script of TOS: "Miri", "some wild looking surfing boards" were said to be included inside Biggs' toy store.


text:
Product Spotlight
Featured Research
Quick Stats
You are here
Woes Persist for Ahold's U.S. Business
AMSTERDAM -- Dogged by rumors that the results of its strategic review will include an announcement that it's found a buyer for its troubled U.S. Foodservice division, Ahold yesterday reported sliding third-quarter identical- and comparable-store sales for most of its American supermarket operations.
AMSTERDAM -- Dogged by rumors that the results of its strategic review will include an announcement that it's found a buyer for its troubled U.S. Foodservice division, Ahold yesterday reported sliding third-quarter identical- and comparable-store sales for most of its American supermarket operations.
"We stated when we announced our Q2 results that the outlook for the second half of the year would be more challenging," said the retail conglomerate, which posted net sales of 10.3 billion euros for the quarter, in a statement. "The third quarter has been even more challenging in the United States, reflecting increased competitor activity and weaker economic conditions, leading to margin pressure."
Compared with the year-ago period, Ahold's net sales increased 0.7 percent and 3.7 percent at constant exchange rates.
In the Stop & Shop/Giant-Landover Arena, however, although net sales grew 2.1 percent, to $3.7 billion, identical sales declined 1.3 percent at Stop & Shop (1.8 percent excluding gasoline net sales) and 0.5 percent at Giant-Landover, while comparable sales dipped 0.8 percent at Stop & Shop and 0.2 percent at Giant-Landover.
The Giant-Carlisle/Tops Arena reported net sales of $1.4 million, a 0.3 percent increase, but identical and comparable sales were mixed. While identical sales grew 4.8 percent at Giant-Carlisle (3.0 percent excluding gasoline net sales), they plunged 6.2 percent at Tops (7.3 percent excluding gasoline net sales). Similarly comparable sales surged 7.2 percent at Giant-Carlisle, but fell 5.7 percent at Tops.
At U.S. Foodservice, locus of Ahold's massive 2003 earnings-overstatement scandal, net sales increased 5.0 percent, to $4.5 billion. However, quarterly sales comparisons declined about 0.7 percent, due to U.S. Foodservice's exit from the Sofco business in the third quarter of 2005. Cost inflation was in the 1 percent to 2 percent range for the third quarter.
Net sales at U.S. Foodservice's Broadline division grew 4.3 percent, to $3.9 billion, although the Sofco exit in the year-ago period adversely affected Broadline sales by about 0.8 percent. Meanwhile net sales at the North Star Foodservice arm jumped 9.6 percent, to $684 million.
Among Ahold's European businesses, Albert Heijn performed best, with an identical sales rise of 9.2 percent, while the company's Central Europe Arena reported a plunge in identical sales of 6.1 percent. Citing no sources, Dutch financial publication has reported that Ahold would sell off its underperforming Polish and Slovakian divisions, as well as U.S. Foodservice, to facilitate a merger with Belgian retailer Delhaize.
Additionally Ahold's shareholders, led by two hedge funds, have been pressuring the company to sell off all of its American businesses and concentrate on its core European markets to regain financial health.


text:
Definition Edit
Intelligence discipline is
|[a] well defined area of intelligence collection, processing, exploitation, and reporting using a specific category of technical or human resources.[1]
Overview Edit
There are seven major intelligence disciplines:
- Human intelligence (HUMINT)
- Geospatial intelligence (GEOINT)
- Measurement and signatures intelligence (MASINT)
- Signals intelligence (SIGINT)
- Open-source intelligence (OSINT)
- Technical intelligence (TECHINT) and
- Counterintelligence (CI).
References Edit
- ↑ U.S. Department of Defense, Joint Pub. 1–02: DOD Dictionary of Military and Associated Terms (Nov. 8, 2010, as amended through May 15, 2011) (full-text).


text:
The Department of Health, Physical Education and Recreation will host the 13th annual Wellness Fair at Plymouth State College from noon – 3 p.m. Monday, October 22 at the Hartman Union Building on High Street.
Wellness Fair Coordinator Mardie Burckes-Miller says the program will include free health screenings for cholesterol, glucose and oral health, entertainment, seminars, more than 50 exhibits, and door prizes.
Seminars are scheduled on "Masculinity and Media," "How To Be Your Own Personal Trainer," and "Managing Stress."
Entertainment will be provided by The Plymouth Players, The Baker Valley Cloggers, Plymouth Ballet Dance Studio, and The PSC Contemporary Dance Ensemble.
For information contact Dr. Mardie Burckes-Miller at 535-2515.


text:
There's something about the spawning Chinook salmon and the effectiveness of hot orange egg patterns for Rogue River steelhead during October. Why not fish two flies in one pattern? 72 more words
Tags » Selbicky's Magic Fly
August Rogue Weather
This spate of extremely hot weather is bothersome and yet welcomed. I makes time to catch up with some fly tying. My bins are now full! 8 more words


text:
In a move that is likely to worsen relations between Afghanistan and Pakistan; the Afghan government has moved to block the entry of all Pakistani newspapers. In its order, the interior ministry of Afghanistan said that the newspapers "are a propaganda resource of the Taliban spokesmen".
According to the ministry Pakistani newspapers are usually filled with statements that the Afghan government has failed to represent its people and that its NATO-led allies have a strong hold on the country. "We totally reject these statements and the ban is to show them this," said Ihsanuddin Taheri. He also said that some Pakistani newspapers also publish speeches made by Taliban leaders. This is not a responsible move especially, at a time when the government is trying hard to engage Taliban in negotiations aimed at ending the 11-year Afghan war.
Experts suggest that the ban of Pakistani newspapers in Afghanistan will further strain the relations between the two neighboring states.
Afghanistan has urged Pakistan to immediately stop shelling in the border province of Kunar. Cross-border violence has become a sensitive issue in Afghanistan and this was verified by the Afghan foreign minister when he told the UN Security Council in New York that diplomatic ties with Pakistan were under threat.
Meanwhile, senior journalists from Afghanistan stressed that media persons from both countries should sit together to discuss how to convey truth without making use of any propaganda techniques. "I believe that the ban on Pakistani newspapers is no solution and I do not support such curbs," said President of the National Union of Journalists of Afghanistan Abdul Hameed Mubariz.
Another senior journalist Sami Yousufzai who reports for Newsweek magazine also described the ban as an unwelcoming move by the government. "Many Pakistani newspapers, especially the English ones, have adopted a balanced approach towards events," he said. However, all of them agree that the currently prevalent border tensions may have led to the ban on Pakistani media publications.


text:
ALMA MEDIA CORP.STOCK EXCH. ANNOUNCEMENT 10 SEPT. 2001, 13.00 AM ALMA MEDIA PLANS BOND LAUNCH Alma Media is planning to issue EUR 50 million in bonds, principally to domestic institutional investors, under its EUR 100 million medium term note programme. The bonds will be offered for sale from today. Sampo Bank Plc has been retained as the programmes lead manager. The bonds mark the launch by Alma Media of a publicly listed debt instrument and at the same time expand the companys sources of long-term financing. The bonds, which will total EUR 50 million, will be issued in one instalment under the book-building method on 4 October 2001. The bond premium will be variable and its coupon rate will be determined later. The maturity period of the bonds will be five years (4 October 2001 4 October 2006) and the minimum subscription lot will be EUR 100,000. The company will make its final decision on the bond launch after the close of the sale period based on offers made by investors. Alma Medias intention is to apply for listing of the bonds on the HEX Helsinki Exchanges for public trading after the bonds are issued. Alma Media Corporation Ahti Martikainen Vice President, Corporate Communications and Investor Relations Further information: Mr Timo Ruotsalainen, Manager - Treasury, Alma Media Corporation, tel. +358 9 507 8760, +358 40 730 5661 Ms Riitta Salonen, Senior Vice President, Head of Capital Markets, Sampo Pankki plc, tel. +358 10 513 3633 Distribution: HEX Helsinki Exchanges, Principal Media
- Date: 10.9.2001, 08:00
- News type: Stock exchange release
Release subscription form
NOTE. If you fill in your phone number, you will automatically receive the subtitles of the releases also as SMS. If you do not wish to receive SMS's from Alma Media, simply leave the phone number field empty.


text:
The Saint Augustine Community Band was originally established back in the early 1900's with a small military style band of about 16 members. Unfortunately, as the years went by and with the impact of the depression, the band eventually disbanded in 1950. Over the years there were a few attempts to form a local community band but nothing ever survived long-term.
Today, after nearly 65 years of dormancy, the 70 member Saint Augustine Community Band is back in full force. Members range in ages from 16 to 80 including high school students, amateurs and semi-professionals from all walks of life. The band was re-formed in September of 2015 under the baton of Maestro Geoffrey S. Magnani, who retired in Saint Augustine from New York State. There were 38 members in the initial group but within the year the membership has blossomed to 70 and still growing. The goal is to offer instrumentalists in Saint Augustine and surrounding areas an opportunity to play in a band that is based in the city known for its rich heritage, culture and history. Members come from as far as Jacksonville south to Palatka to play in the band.
With the strong prevalence of the arts in Saint Augustine, the city finally has its very own concert band back!


text:
- Home /
- Smith Frontman Sunglasses Matte Camo / Polarized Gray
Product Description
Details: Smith Frontman Sunglasses Black / Polarized Gray Green
Front and center with bold charisma and distinction. The Frontman has crisp and fresh surfacing details, plus enough head curvature and temple thickness to keep out the sun, stage lighting, and glare of your adoring fans.
- Evolve frame material
- Hydrophilic megol nose and temple pads
- Auto-lock hinges
- Medium-large fit / large coverage
- 8 base lens curvature
- Frame Measurements 61-17-125
- Polarized Gray: Polarized Gray reduces reflected glare and sharpens detail in true colors. Anti-Reflective (A/R) mirror coating eliminates back glare. Hydroleophobic coating repels water, dirt, and grease. Provides 100% protection from harmful UVA/B/C rays.
We have the Smith Frontman Sunglasses Black / Polarized Gray Green in stock with Free Shipping in Canada.
We are proud to be an Official Partner with Smith Optics in Canada.
Additional Information
Additional Information
Accessory Set Misc Accessory Type Sunglasses Colour Camo Season Carry Over Brand Smith
Easy Returns
Do you want to return something? No problem!
- At Pacific Boarder we value our customers, always trying to meet their expectations. We understand that sometimes the item you ordered is not exactly what you were looking for or it doesn't fit perfectly.
- In this case simply return it in its original condition within 30 days of shipped date and we'll exchange it, issue store credit or refund it.
- **Please note that all Swimwear and Underwear is final sale and cannot be returned
- Find out more about our Return Policy.
Free Shipping
Now is the time to get geared up! Spend $100.00 or more and receive Free Shipping* on your order! *Full Details HerexPrice:Actual Price:Our price is lower than the manufacturer's "minimum advertised price." As a result, we cannot show you the price in catalog or the product page.
You have no obligation to purchase the product once you know the price. You can simply remove the item from your cart.Our price is lower than the manufacturer's "minimum advertised price." As a result, we cannot show you the price in catalog or the product page.
You have no obligation to purchase the product once you know the price. You can simply remove the item from your cart.
Shop With Confidence . . .
Exceptional customer service – 1.888.262.7337
Free Shipping on orders over $100*
Price Match Guarantee
Hassle Free Returns
Helpful Links . . .
Contact Us . . .
Call Us 1.888.262.7337
You Ask, We Answer!
Drop us an email.


text:
Warning: By law we cannot sell this product to anyone under 18, by placing an order with us you are confirming that you are over the age of 18.
Tom Ford
In stock
Grey Vetiver Eau de Toilette
£53.50 – £71.00
This is a specialist veterinary product. We will ask you a simple set of questions to confirm that you are buying the correct medicine for your pet and know how to use it safely
Order by 3pm for Express Courier Delivery Some of the items we sell are a bit too bulky to fit on our delivery vans so we offer our customers Express Courier Delivery via courier. Deliveries are made from 8am - 8pm Monday to Saturday and 9am - 5pm on Sundays. Your delivery slot will only be confirmed once your order has been placed.
"Vetiver immediately evokes for me the classic man, someone who has a confident, refined, and slightly traditional sense of what it means to be a man - an elegance that is mirrored in Tom Ford clothing. It's one of my favourite fragrance notes because it is timeless, grounded, and has an enormous amount of character" says Ford. TOM FORD GREY VETIVER has been crafted around the most authentic Vetiver note available and moves it from the background - the ingredient's traditional placement in many fragrances - to a signature placement from top note through long-lasting dry down. To construct Grey Vetiver's stunning character, this exclusive extract is used in far greater quantity than Vetiver is traditionally used in many scents. Surrounded by notes selected to support and enhance the Vetiver signature, the result is an extremely luxurious fragrance that is powerfully recognisable: TOM FORD GREY VETIVER is a composition of silvery, tailored elegance over a background of compelling, ground


text:
This Way And That Socks by Debbie O'Neill
Welcome! You are browsing as a guestWould you like to see 11 projects made from this pattern and much more? create a free account What am I missing?
This Way And That Socks
This pattern is available for $5.00 USD buy it now
This sock is sized in women's small (medium, large, extra large).


text:
"Wonderful care at a difficult time"
About: Queen's Hospital, Burton Upon Trent / Maternity care Queen's Hospital, Burton Upon Trent Maternity care DE13 0RB
Posted by Curtains (as ),
Sadly my wife and I had the tragic misfortune to suffer a miscarriage at 19 weeks. She was rushed to Burton hospital late on a Friday night to see what was going on and to look after her as she was bleeding quite heavily.
On arrival we were looked after brilliantly, told with care and compassion about everything that was going on, and were able to make informed decisions even though all around us it felt like our world was collapsing in.
Over the next 24 hours we experienced great trauma both emotional and physical and throughout the Burton Hospital midwife team were angels, to a person. They gave us the info we needed, looked after my wife and I, respected our wishes, provided excellent nursing care, and engaged with us personally in a way that was inspiring and everything that is great about the NHS.
Once it was all over the bereavement midwives stayed in touch and even came to the remembrance service with us and hugged us afterwards.
I'm not usually one to be sentimental but they were our angels through that awful night.
Response from Gay Vaughan, Corporate Development Officer, Burton Hospitals NHS Foundation Trust 3 years ago
Thank you for taking the time to post your comments at a very sad time to you and your family and we sincerely empathise with you.
We aim to deliver our care in a professional, caring manner and treat all of our patient's in a way that they would expect to be treated.
We will share your comments with the staff that have been involved with your care.
Once again, thank you for taking the time to post you comments at a very distressing time.
- {{helpful}} of {{total()}} people think this response is helpful
- Was this response helpful? Yes | No
Thank you for your feedback.
See more responses from Gay Vaughan


text:
What to do if you can't afford to pay the UWA Student Services and Amenities Fee
What if I can't afford to pay the UWA Student Services & Amenities Fee (SSAF)?
If you cannot afford to pay your UWA Student Services and Amenities Fee by the due date due to financial hardship, eligible students (Australian citizens, permanent humanitarian visa holders resident in Australia and New Zealand Special Category Visa holders who meet the long-term residency requirements) can request assistance from the Commonwealth and defer the fee through the SA HELP scheme.
Financial assistance for students in genuine financial hardship may also be available from the University and the Guild.
The University may provide assistance to students through its Student Loan Scheme. To qualify for a loan, you must be currently enrolled in an approved course of study at the University of Western Australia. Other eligibility criteria include:
- Genuine financial hardship: loans will only be considered where genuine financial hardship is established and you can demonstrate that a loan is essential for you to continue your current course at this University.
- Academic record: you must demonstrate that you have the capability to complete your current course successfully. Therefore your academic record is a factor in the assessment of your loan application.
- Other possible sources of income: if you have other possible sources of income such as assets, fixed term deposits, loans from family members etc. you should investigate such avenues before applying. Loans will not be issued for pre-existing debts, fines, house or property improvements and other expenses not directly related to essential course-related endeavours. Loans will not be provided to pay University/HECS fees.
For more information:
Australia Citizens & Permanent Residents Contact:
Student Financial Aid and Housing Officer
Student Support Services, Student Central
The University of Western Australia
35 Stirling Highway, Crawley WA 6009
Telephone: (08) 6488 3547 Fax: (08) 6488 1119
Website or E-mail
International Students Contact:
International Student Adviser
The University of Western Australia
35 Stirling Highway, Crawley WA 6009
Telephone: (08) 6488 2423 Fax: (08) 6488 4071
Guild Student Centre
Ground Floor Guild Village
The University of Western Australia
35 Stirling Highway, Crawley WA 6009
Telephone: (08) 6488 2295 Fax: (08) 6488 1041
Website or Email
UWA Student Guild
In addition, the Guild offers comprehensive student financial assistance package to support students with course-related expenses, including the UWA Student Services and Amenities Fee.
Study Support Fund for Women
Female students at UWA studying a minimum of 12 credit points per semester, who are either an Australian citizen or the holder of a Permanent Resident Visa and having lived in Australia continuously for at least 2 years prior to making application, may be eligible to apply for a grant of up to $2000 from the Study Support Fund For Women.


text:
Southern Caviar
READY IN: 5mins
Recipe by South Carolina Girl
A friend's family makes this regularly, and it's so good that I asked for the recipe so that I could have it more often.
Ingredients Nutrition
- 15 ounces black beans, rinsed and drained
- 16 ounces black-eyed peas, rinsed and drained
- 10 ounces Rotel diced tomatoes, not drained (original or hot)
- 11 ounces canned white shoepeg corn, drained
- 3 roma tomatoes, seeded and diced
- 1 green bell pepper, seeded and finely chopped
- 3 -4 green onions, thinly sliced
- 3⁄4 cup KRAFT Zesty Italian Dressing
Directions See How It's Made
- Mix all of the ingredients except the chips.
- Refrigerate.
- Serve with chips.


text:
Race one was F2-3, a blinding start was made by Stuart Riches who cleared the fleet on Port however couldn't hold the position as the fleet split. The left side won the battle and this repeated on second lap. Final position was a Junis Rindermann first with Jon Heissig second.
Race 2 was F3 and the fleet split again with Jerry Wales, Steve Powell, Tony Dencher and Stuart Riches meeting at windward mark. After some changing places thoughout Jerry Wales took line honours with Tony Dencher second.
Race 3 was the most exciting race with a good F4 and an excited fleet. Many racing incidents, lots of upside hulls made a busy race track. Simon Letten took a big tumble and lost the battle with the rudder blade but the good news is the RS Doc has given him the all clear and is sporting a big bandage! Line honours Tony Dencher again
Race 4 was much the same with a falling breeze but the highlight was RS guru Alex Southon finally making an appearance at the front end with a well deserved fifth. By the way Alex now sails for Outerbagdad Sailing Club. Why?
Last Blast Tuesday for the RS700's: The final days racing finally served up some wind allowing the boats to show their speed and the helms to finally stretch their legs. As a result the leader board for the days racing looked very different again.
Race started in a strong F4 and it was Alex Newton-Southon who powered out of the start line, went right up the beat to lead the race from start to finish. Steve Powell who still had a mathematical chance of taking the championship, followed at a respectful distance but ahead of Jon Heissig. Championship leader had an uncharacteristic swim and ended up in fifth place. The other podium contender Mike Dencher suffered a kicker failure and had to retire from the race to make a jury repair.
The second race started in a strong but weakening F4 breeze with the championship still mathematically open with Stephen Powell snapping at the heels of a very in form Jerry Wales.
This time going up the middle appeared to play but once again it was Alex who lead at the windward mark a short length ahead of Ian Nolan. These two shot off downwind and pulled some distance on a chasing Mike Dencher. Alex was going higher and faster than the rest of the fleet but still looked good to cross ahead on the first gybe, if only he hadn't dropped it at the wrong moment. This left Nolan with a small lead which he protected through to the finish, with Mike Dencher second, Jerry Wales third and Mark Pollington fourth.
Stephen Powell unfortunately tried to bang right on the first beat which proved the wrong tactic and left him in mid fleet guaranteeing Jerry Wales the championship. Mike Denchers second in the last race moved him onto third overall by one point from Jon Heissig fourth.
Thanks go to Sailboat deliveries for sponsoring the event and to WPNSA for putting on a great event.
RS Association website


text:
Italian Flavored Tempeh Nuggets
Recipe by Kozmic Blues
These are amazing! When these cook, the balsamic marinade becomes a delicious caramelized coating. Use these nuggets over salads, over rice or to accompany pasta. They make great little finger snacks too. Cooking time does not include marinade time.
Top Review by eliseghitman22
Oh, yum. These are crispy, crunchy, flavorful, deliciousness. I added some korean veggie stir-fry sauce to the marinade(I bought mine at Stop 'n' Shop, I highly reccomend it). These are super simple to make- perfect for a healthy, vegan meal in a time crunch. Loved it!
See Discussion:22 Reviews 1 Tweak
Ingredients Nutrition
- 8 ounces tempeh
For the marinade
- 1 tablespoon olive oil
- 2 1⁄2 tablespoons balsamic vinegar
- 2 1⁄2 tablespoons soy sauce
- 2 garlic cloves, minced
- 1⁄4-1⁄2 teaspoon red pepper flakes (to taste)
- 1 teaspoon dried thyme
- 1 teaspoon dried basil
- 1 teaspoon dried rosemary, crushed between fingers
Directions See How It's Made
- Cut tempeh into 1/2 inch wide cubes.
- Combine the marinade ingredients in a container with a lid, stir to combine.
- Add tempeh, cover and shake well until all pieces are coated.
- Pace in refrigerator for one hour or overnight.
- Shake container every now and again (when you think of it) to coat all pieces. The tempeh will begin to absorb all the marinade.
- When ready to cook, heat a non stick skillet over medium low heat.
- Add tempeh and any liquid and cook for about 10 minutes, turning pieces until they begin to caramelize.
- Serve immediately or keep in a covered container in fridge.


text: Located in the prefecture of Tochigi in Imaichi City, this restaurant has been serving customers unagi (freshwater eels) for over a hundred years. The restaurant carefully selects and cleans the eels using fresh water sprung in Imaichi, ensuring the quality of their dishes. Next, the eels are then grilled on special charcoal and seasoned with the restaurant's secret soy sauce mixture. This unagi restaurant is open daily, except on Mondays and on the third Sunday of each month, from 11:30am to 9pm. Lunch is served from 11:30am to 2pm, while dinner is served from 5pm to 9pm.


text:
Howard Hewett: Once Twice Three Times MP3
After the break up of Shalamar Hewett's second album spawned this single. From the 1988 Album Forever And Ever.
Lionel Richie - Three times a lady 2007 live MP3
Lionel Richie - Three times a lady live 2007 Released 1978 Thanks for the times That you've given me The memories are all in my mind And now that we've ...
Three Times A Lady - COMMODORES & LIONEL RICHIE. MP3
You're once, twice, three times a lady And I love you Yes, you're once, twice, three times a lady And I love you I love you.
Howard Hewett - Once, Twice, Three Times MP3
Lionel Richie - Three times a lady + lyrics MP3
Lionel Richie - Three times a lady. + lyrics.
Commodores - Three Times A Lady [Live] MP3
Commodores - Three Times A Lady.
Lionel Richie - Three times a lady MP3
Live 2007.
Starcraft 2 - Infested - Brutal (Once, Twice, Three Times Malady Achievement) HOTS MP3
Starcraft 2: Heart Of The Swarm - Once, Twice, Three Times Malady Achievement on BRUTAL Difficulty: Complete the "Infested" mission before the Dominion ...
Infested: Once, Twice, Three Times Malady Achievement Guide MP3
A commentary guide to the NAME Mastery Achievement for the Starcraft 2 Heart of the Swarm campaign. Please subscribe: ...
Infested - Speed Run - Once, Twice, Three Times Malady Guide - Starcraft II: Heart of the Swarm MP3
This video walkthrough guide covers the campaign mission "Infested" from the video game Starcraft 2 Heart of the Swarm, showing how to unlock the mission ...
Starcraft 2 Once, Twice, Three Times Malady Infested Achievement Guide MP3
http://www.osirissc2guide.com/starcraft-2-infested-brutal-mode-and-achievements-guide.html - Text and video guides for the HotS mission, "Infested", including ...
The Commodores - Three Times A Lady MP3
Dedicated to my love My heart is complete With the love we share, And our love grows more Beautiful each day. I love you, And as long as we are together, ...
The Commodores - Three Times A Lady - Long Version MP3
The extended version (about 6min 35sec) of THREE TIMES A LADY By The Commodores.
Howard Hewett - Once, Twice, Three Times (LIVE Audio) MP3
from "Intimate LIVE" Official Howard Hewett Pages: Facebook: http://www.facebook.com/howardhewettfanpage Twitter: http://www.twitter.com/justavocalist ...
Hannah Montana s03e15 Once, Twice, Three Times Afraidy MP3
Miley tries to convince Lilly and Oliver that she likes being single, but they keep trying to set her up with dates. When she meets Traci's boyfriend "faux beau" ...
your once twice three times a lady (FROM THE MOVIE 'WHAT'S YOUR NUMBER') MP3
I love this song!
Heart of the Swarm Guide: "Once, Twice, Three Times Malady" Achievement MP3
Thank You SO much for every Like/Favorite! Subscribe to join Earthlings! Like QSTV: http://www.facebook.com/QuickSaveTV Follow QSTV: ...
B5-039529 once, twice, three times a robbery MP3
It looks like this guy is on a spree, but this time he brought a clumsy and confused friend. You can really hear the robber's voice in this video so we are hoping ...
Once, Twice, Three Times a Larry MP3
all guys.
Howard Hewett Live Performance, "Once Twice Three Times," MP3
Howard Hewett singing one of my favorite songs of all time, "Once, Twice, Three Times" at a jazz festival in Columbia MD on 6.8.08. Brought to you by ...
Nine Below Zero - Once Twice Three Times Is Enough MP3
Nine Below Zero records live at Epic Studios. Follow us on twitter @epicnorwich, Like us on Facebook at EpicStudioNch or see what's happening on ...
Seinfeld_ The_ Pothole MP3
Elaine is pretending to be a janitor at the building across the street from her because the chinese rest. won't deliver to her side of the street. She is in the process ...
Learn Spanish Essentials (1) Lets-Learn-Spanish.com: "Once, Twice, Three Times" MP3
FULL VERSION: http://www.lets-learn-spanish.com/vocabulary-genius/ In this short video I'll show you an easy way to express things like once, twice, three ...
SC2 Heart of the Swarm - " Once, Twice, Three Times Malady " Achievement Guide (Hard Difficulty) MP3
Achievement Description: Complete the "Infested" mission (Skygeirr mission 1) before the Dominion gas the platform a 3rd time on Hard Difficulty.
Hannah Montana Season 3 Episodes 15 Once,Twice,Three Times Afraidy Full Episodes 720p MP3
Once, Twice, Three Times a Monkey : June 22, 2015: BTD5 Bloons Daily Challenge MP3
NAPS(F)RIS. Very close to NAPS(F)RILLS. Place some extra towers during the round to get NLL. 2015-06-22 ----- Acronym guide: NAPS = No Agents, Premiums ...
IWALVG Dumpster Dives - Once, Twice, Three Times An Xbox!! MP3
A THIRD Xbox 360 is found in a GameStop dumpster... Neil and Herbie see if it was worth the save! ▻ The last time the boys discovered an Xbox 360: ...
Once, Twice, Three Times A Liar MP3
Political Parody of Lionel Ritchie's great song, Three Times a Lady.
Get It In Once Twice Funny MP3


text:
It's crazy given my age, which I won't go on about (ahem), but weekends are a new thing for me.
I like weekends.
I finally get the TGIF posts. At work last night toward the end of my shift, I thought, "huh, when I leave I'll have 2 days to lie around and do whatever I want. Cool!" I actually have a freelance work that will keep me busy, and I have a bunch of stuff to do around the house, but still. Weekends = awesome.
Somehow I never felt like I had "time off" from the ER. Either I was catching up on sleep or I was on call, seemed like. I chose to work weekend option, so it's not the concept of the specific days Saturday and Sunday. I just didn't have any fixed interval where I felt free.
The regularity of the same hours, basically, with days in between with no call, is a major benefit. I'm loving it. Now I need to stop reveling in my freedom and get some editing done.


text:
Summer 2014
Please indicate whether you will be celebrating your accomplishments with us.
We would love to see you again!
Date: August 20th
Time: 3-5pm
Location: Faculty House at Columbia University
64 Morningside Drive
New York, NY 10027
Congratulations, new Edmodo Certified Trainers!
Encapsulate your experience by answering the question "How do you Edmodo?"
Focus on ONE important feature, teaching strategy, or take-away from the training that you would like to highlight. Then create something original to communicate this such as a video, a brochure, a presentation, or a digital flyer. You can even use an Edmodo app to create your masterpiece.
Then submit your contribution in the comment stream below in the form of an image or a link. You can even share a Google Doc.
The 3 best contributions, based on your votes, will receive special recognition awards.


text:
Hey there, time traveller!
This article was published 10/5/2013 (1564 days ago), so information in it may no longer be current.
DEAR MISS LONELYHEARTS: I just read the letter from Need Tips, who was looking for ways to make sure a marriage stays warm and loving and lasts a lifetime. Her young man wanted ways to guarantee that's what happens. Life offers none of us any guarantees, but my high school sweetheart and I will be celebrating 22 years of marriage this October, plus seven years of dating before. People often tell me how lucky I am, but luck has nothing to do with it. A long-term relationship is not fireworks every day and it takes work to make it last. Always remember to communicate with each other and respect each other. With respect there is admiration, support and a deep friendship which sustains the deep love you will both have for one another. We have relied on these principles to pull us through the difficulties of life. You may not be able to see what is coming around the next bend, but is sure is awesome knowing you have a spouse that always has your back. -- 29 Years of Love, Winnipeg
Dear 29: The hardest part is often riding through the lulls or backslides in intensity and warmth found in any long marriage. A campaign initiated from one side or both, to take on a new adventure together -- travelling, building, joining something new as a couple -- can bring you back quickly to getting a big kick out of each other.
Dear Miss Lonelyhearts: This letter is in answer to Need Tips, who was seeking advice, preferably from elderly men with experience. My wife and I -- now in our 70s -- celebrated our golden wedding anniversary two years ago. We had courted for four years before our marriage for a total of 56 years of wonderful courtship and marriage. My secrets to a wonderful marriage? Say "I love you" in the morning when you awaken and every evening when you go to bed. Say "I love you" every time you part and every time you meet -- actually any time or place with honesty and feeling. Hold hands when you're out together, hug a lot, kiss often and never be embarrassed at tastefully showing your affection for each other in public. Write affectionate notes to each other often. When apart, contact each other daily. Include parents, your children and grandchildren in your life, if you are so blessed. Send personal, hand-written cards. Never forget your loved one's birthdays, anniversaries, special days, special dates, special celebrations. Say "please" and "thank you" all the time. Send flowers. Never part in anger or when upset with each other. Talk it through. and say "I'm sorry" -- go more than halfway if need be. Laugh together, often and loudly and do it in public without embarrassment. Look for any opportunity to pay a compliment to your partner. Today is all we have -- it is a gift to us. A friend, in her moving eulogy to her young husband who had just died, taught me that in life we only have today to live, so treat your loved one with this in mind. Love them always as if there is no tomorrow -- one day there will be no tomorrow. -- Love Makes All Possible, Winnipeg.
Dear Possible: What would we do differently today if it were the last one left with your loved one? My kids and I say "love you" instead of goodbye. If it were the last time we saw each other, that would be the last thing we exchanged. It would be nice if all couples were as nice to each other as adults are with their kids, instead of subconsciously keeping score and dishing out words and affection, "as deserved" that day or week.
Questions or comments? Please email firstname.lastname@example.com or send letters c/o Miss Lonelyhearts, 1355 Mountain Ave. Winnipeg R2X 3B6


text:
Contact Houston Site Acquisitions
Thanks for visiting. We want your business. We are in business for Houston's business. Call us, fill out the form, email us, or schedule an appointment with us. Our office is located in downtown Houston, the heart of Houston's Central Business District within the Main Street-Market Square Historic District and is conveniently located on the Main Street-Preston Light Rail Station.
Link To Us
Copy and paste the HTML code below to link to our site. Contact us after the banner is on-line for consideration and review.


text: 1 photos $610,000 0.5 acres 4 Beds | 3 Baths | 1 ½ Bath | 2 sqft 3400 Lake Chapin Dr., Berrien Springs, MI 49103 - Berrien County Developer Closeout - Lake Chapin Shores Developer Closeout. Last lot available at Lake Chapin Shores comes with slip in marina and garage unit. Enjoy beautiful Lake Chapin Shores on all sports Lake Chapin with Pool, sundeck, marina and common areas with playground. This home, the Fox Run is a beautiful 3 level home with 4 bedrooms and screened in porch all with high end finishes. Pick out your colors and make any changes to make it your own. Lower level walkout with bedroom, family room and wet bar. Devloper licensed agent in MI Steve Sprengel Michigan Lakeside Properties


text:
Yes it's true. Salman Khan starrer Judwaa, which was a blockbuster hit in in the year 1997, is all set for a sequel titled, Judwaa 2, and this time Salman Khan will not play the lead role in the movie. The role has been bagged by none other than, Varun Dhawan.
For quite a long time, rumours were abuzz that David Dhawan would cast his son Varun, in Judwaa 2, and now the actor himself confirms that he's a part of the movie by posting a picture on Twitter.
Varun Dhawan, took to Twitter and posted a picture wearing a blue leather jacket and captioned it as "#Judwaa2".
However, no further details are given out by the actor about Judwaa 2 and we're sure the sequel would be a laugh riot, just like its prequel.
Also Read: 10 Spectacular Pics Of Deepika Padukone From Instagram In 2016
Since the title of the movie itself is Judwaa 2, it's quite obvious that we would get to see Varun Dhawan playing a double role. Salman Khan, delivered the best in Judwaa in 1997, and it's now Varun Dhawan's turn.
We never know, Salman Khan might also return on-screen for Judwaa 2 along with Varun as well! Watch this space for further updates! Judwaa 2, is quite interesting.
Also Read: BIKINI PICS: 10 Cupcakes That Match Sunny Leone's Bikinis


text:
The past year has brought advances in the treatment of a broad range of cancers. From November 2015 through October 2016, the FDA approved eight new cancer treatments and 12 new uses of previously approved cancer therapies (Table 1). The new approvals include immunotherapies for bladder cancer and multiple myeloma and targeted treatments for hard-to-treat forms of lung and kidney cancers, chronic lymphocytic leukemia (CLL), and multiple myeloma. New-use approvals have broadened treatment options for patients with melanoma, sarcoma, CLL, lymphoma, neuroendocrine tumors, and breast, lung, kidney, and head and neck cancers. In addition, the FDA approved the first liquid biopsy test in 2016.
Each year, 14 million people around the world learn that they have cancer. Because cancer is mostly a disease of aging, cancer occurrences are expected to increase as human lifespans are extended. Although prevention is the ultimate goal, many factors that contribute to cancer cannot be controlled. Advances in cancer treatment will therefore remain a key part of reducing the global burden of cancer.
Targeted Therapy
In addition to the growing success seen with immunotherapy, 2016 was marked by a wave of advances in precision medicine–based approaches. They include treatments directed at novel molecular targets, new types of treatment, and new ways to combine traditional cancer treatments.
After 20 years, a promising new treatment of acute myeloid leukemia.
Acute myeloid leukemia (AML) is the second most common type of leukemia diagnosed in both adults and children. In 2016, an estimated 19,950 people of all ages in the United States were diagnosed with AML. This type of cancer is difficult to treat, and only 27% of patients survive 5 years after diagnosis.46 More information on AML can be found on Cancer.Net.
There have been no effective new treatments for AML since the 1990s. In 2015, researchers reported preliminary findings, which may lead to a new standard of care for approximately one-third of patients with AML, those with mutations in a gene called FLT3 (this study was funded in part by a grant from the NCI).47 Patients with FMS-related tyrosine kinase 3 (FLT3)–positive AML have a poor prognosis and a high chance of relapse.
In a large clinical trial, previously untreated patients who received a therapy targeting FLT3 called midostaurin, combined with standard chemotherapy, lived years longer than those who received chemotherapy alone. The median survival was 75 months among patients who received midostaurin with chemotherapy and only 26 months among those who received placebo with chemotherapy. Midostaurin also more than doubled the median event-free survival (defined as death, relapse, or no complete remission within 61 days) achieved with chemotherapy alone (8 v. 3.6 months).
The overall rates of severe adverse effects and treatment-related deaths were similar between the midostaurin and placebo groups. With 717 patients, this is the largest clinical trial of patients with FLT3-positive AML to date to our knowledge.
New treatment targeting common marker improves outcomes after acute lymphoblastic leukemia relapse.
In 2016, an estimated 2,636 adults in the United States were diagnosed with acute lymphoblastic leukemia (ALL).48 Although a majority of adults with ALL achieve complete remission after initial therapy, many eventually relapse. The prognosis for such patients is poor, and more effective treatments are urgently needed.
One new treatment, inotuzumab ozogamicin, may improve outcomes for older people with recurrent ALL, according to an ongoing clinical trial.49 Inotuzumab ozogamicin belongs to a new class of cancer treatments known as antibody–drug conjugates (ADCs). These comprise an antibody chemically linked to a powerful cancer drug called calicheamicin. The antibody targets the CD22 molecule, found on tumor cells in 90% of patients with B-cell ALL, and helps deliver calicheamicin to leukemia cells.
In this late-stage trial, patients were randomly assigned to receive inotuzumab ozogamicin or standard intensive chemotherapy. The rate of complete remission was more than two-fold higher in the inotuzumab ozogamicin group compared with the standard therapy group (81% v. 29%). The median time until cancer worsened was longer in the inotuzumab ozogamicin group than in the standard therapy group (5 v. 1.8 months), and the median survival was longer as well (7.7 v. 6.7 months).
A major adverse effect of inotuzumab ozogamicin was veno-occlusive liver disease, which occurred in 11% of patients. Inotuzumab ozogamicin is likely to become a new standard of care for older adult patients with relapsed or refractory B-cell ALL.
Progress in treating advanced, ALK-positive NSCLC.
Approximately 3% to 7% of NSCLCs are anaplastic lymphoma kinase (ALK) positive, meaning that the cancers carry a genetic change known as ALK gene rearrangement. The first treatment to specifically target ALK-positive tumors, crizotinib, was approved by the FDA in 2011. Although crizotinib shrinks tumors in a large proportion of patients, most experience a relapse within the first year of treatment.
To address the challenge of crizotinib resistance, researchers have been developing more potent, next-generation ALK inhibitors. One such treatment, alectinib, has shown encouraging results in patients with crizotinib-resistant, advanced NSCLC, including those with brain metastases.50 In an early-stage clinical trial, 48% of patients responded to alectinib, with a median duration of response of 13.5 months.
Notably, in 75% of patients with NSCLC and brain metastases, brain lesions shrank with alectinib. This is a promising finding, because chemotherapy has had limited efficacy in the central nervous system (CNS), with response rates of only 45%. In late 2015, the FDA approved alectinib for people with ALK-positive NSCLC who cannot tolerate crizotinib or whose cancer worsens after crizotinib.51 Overall, alectinib was well tolerated, with the most frequently reported adverse effects being nausea and diarrhea. Severe liver enzyme abnormalities occurred in 6% of patients.
Preliminary findings from an ongoing late-stage clinical trial suggest that alectinib may also help previously untreated patients with advanced, ALK-positive NSCLC.52 In this study, tumors shrank in 92% of patients treated with alectinib compared with 79% of those treated with crizotinib. Patients who received alectinib had a 66% lower risk of disease worsening than those treated with crizotinib.
Moreover, alectinib was better tolerated than crizotinib, causing fewer adverse effects. Only one adverse effect, constipation, occurred in more than 30% of patients in the alectinib group. In contrast, several adverse effects, including nausea, diarrhea, vomiting, and visual disturbance, occurred in more than half of patients treated with crizotinib. Another worldwide phase III trial of this same treatment comparison (ClinicalTrials.gov identifier: NCT02075840) is underway.
New regimen halts multiple myeloma progression.
Multiple myeloma is a cancer of plasma cells, which are found in the bone marrow and make antibodies to fight infections. Abnormal plasma cells can crowd out or suppress the growth of other cells in the bone marrow, resulting in anemia, excessive bleeding, and decreased ability to fight infections.
In 2016, an estimated 30,300 people in the United States were diagnosed with multiple myeloma.53 Multiple myeloma often recurs despite treatment. Fewer than half of people with multiple myeloma will live 5 or more years after diagnosis.
Early findings from a late-stage trial suggest that a three-drug combination may improve outcomes for patients with recurrent or treatment-resistant multiple myeloma.54 The new regimen adds the novel therapy daratumumab to a standard combination of bortezomib and dexamethasone.
Treatment that incorporated daratumumab resulted in a 70% lower risk of cancer progression than the standard two-drug regimen. In addition, partial response rates were increased from 29% to 59% with daratumumab, and complete response rates from 9% to 19%. Treatment-related adverse effects were generally similar between the two groups. However, low platelet counts, peripheral neuropathy, diarrhea, and anemia occurred more frequently with the daratumumab regimen.
Daratumumab targets a molecule on plasma cells called CD38. It is one of the first cancer treatments with a two-pronged mode of action: it has the ability to destroy cancer cells directly and coax the immune system to attack the cancer. On the basis of results of an earlier clinical trial, the FDA granted daratumumab accelerated approval for the treatment of multiple myeloma in 2015.
Longer patient follow-up is required to determine if the addition of daratumumab helps patients live longer. Meanwhile, a clinical trial of daratumumab combined with a different standard regimen for patients with recurrent multiple myeloma is underway (ClinicalTrials.gov identifier: NCT01615029). Additional clinical trials testing various daratumumab-based regimens in patients with previously untreated multiple myeloma are also in progress (ClinicalTrials.gov identifiers: NCT02252172 and NCT02195479).
New class of targeted treatments for advanced breast cancer.
Hormone receptor–positive breast cancer is the most common type of breast cancer. Although hormone (antiestrogen) therapy is the standard of care for patients with hormone receptor–positive, human epidermal growth factor receptor 2 (HER2)–negative metastatic breast cancer, its clinical benefit is modest, and treatment resistance remains a significant challenge.
In 2016, researchers reported updated results from a large clinical trial of a new targeted treatment of metastatic breast cancer: palbociclib.55 Palbociclib is a pill that works by blocking two molecules involved in breast cancer resistance to hormone therapy: cyclin-dependent kinase 4 (CDK4) and cyclin-dependent kinase 6 (CDK6). CDK4/6 inhibitors are a new class of targeted treatments that may have a role in many different types of cancer in the future.
The study enrolled women with hormone receptor–positive, HER2-negative metastatic breast cancer that had worsened with prior hormone therapy. Women were randomly assigned to treatment with palbociclib plus a standard hormone therapy (i.e., fulvestrant) or placebo plus fulvestrant. In the trial, the addition of palbociclib to hormone therapy nearly doubled the median time until the cancer worsened to 9.5 months, compared with 4.6 months with fulvestrant plus placebo. Approximately two-thirds of women experienced clinical benefit from the palbociclib regimen, and one-quarter experienced tumor shrinkage. The benefit of palbociclib was seen regardless of degree of hormone therapy resistance, hormone receptor level, and PIK3CA mutational status. However, the rates of severe adverse effects were substantially higher in the palbociclib group (73% v. 22%). The most common adverse effects were low blood counts (neutropenia, anemia, and leucopenia).
Palbociclib has also been studied as initial treatment for advanced breast cancer in combination with hormone therapy. In a large clinical trial, postmenopausal women with estrogen receptor (ER)–positive, HER2-negative breast cancer were treated with either letrozole plus placebo or letrozole plus palbociclib. Palbociclib extended the median time until the cancer worsened from 14 to 25 months in this study.56 The adverse effects among patients treated with palbociclib plus letrozole were similar to those seen previously with palbociclib in combination with fulvestrant (i.e., low blood counts, fatigue, and nausea).
In another clinical trial of first-line therapy for ER-positive, advanced breast cancer, patients were randomly assigned to receive letrozole plus placebo or letrozole plus ribociclib, a CDK4/6 inhibitor.57 In this trial, ribociclib markedly slowed cancer progression. After 18 months, cancer had not worsened in 63% of patients in the ribociclib group, compared with 42% of patients in the placebo group. The clinical outcomes and adverse effects for ribociclib and palbociclib seemed nearly identical.
It is not yet clear if palbociclib or ribociclib will extend overall survival because follow-up has not been sufficiently long nor have any biomarker tests been shown to predict who will or will not benefit from addition of these drugs. However, these findings have already changed the standard of care for patients with hormone receptor–positive metastatic breast cancer. The FDA approved palbociclib plus fulvestrant for women with disease progression after hormone therapy in February 2016.58 Palbociclib was previously approved for use with letrozole as initial hormone therapy for patients with ER-positive, HER2-negative advanced breast cancer.
Voices of Cancer Research: Rona Greenberg
Rona, a breast cancer survivor, had known that having a mutation in the BRCA2 gene increased her risk of other cancers. Still, it came as a shock when she was diagnosed with pancreatic cancer in 2015.
Since then, research advances have helped Rona survive. A targeted therapy called veliparib in combination with chemotherapy shrank the tumors for 10 months. While the treatment eventually stopped working, the potential of precision medicine leaves Rona and her doctor hopeful. She is now on another treatment that holds great promise.
Rona, pictured with her daughters, is a volunteer advocate with Facing Our Risk of Cancer Empowered (FORCE) and Letswinpc.org.
More effective treatments for advanced kidney cancer.
An estimated 62,700 adults were diagnosed with kidney cancer in the United States in 2016.59 Renal cell carcinoma (RCC) is the most common type of kidney cancer in adults. At the time of diagnosis, nearly one-third of patients with RCC have metastatic cancer. The 5-year survival for people with metastatic RCC is only 12%. More information on kidney cancer can be found on Cancer.Net.
Advances in understanding kidney cancer biology led to the development of treatments targeting two molecular pathways: vascular endothelial growth factor receptor (VEGFR) and mammalian target of rapamycin (mTOR). Introduced approximately a decade ago, the treatments extend median survival for patients with advanced kidney cancer from 1 to 3 years. The current standard-of-care treatment for patients with recurrent, advanced kidney cancer includes VEGFR inhibitors axitinib and sorafenib and mTOR inhibitor everolimus.
In 2016, researchers reported findings from a large clinical trial suggesting an even more effective targeted treatment for relapsed RCC.60 Cabozantinib is an oral treatment that blocks several different targets in cancer cells, including tyrosine kinases MET, VEGFR2, and AXL. The median overall survival was 16.5 months in the group of patients treated with standard-of-care everolimus and 21.4 months in the group treated with cabozantinib. Patients who received cabozantinib had a 49% lower risk of cancer progression and substantially higher tumor shrinkage rates (17% v. 3%).
Severe-grade adverse effects that occurred more frequently with cabozantinib than with everolimus included high blood pressure, diarrhea, and fatigue. Anemia was more common in the everolimus group. On the basis of the findings from this study, the FDA approved cabozantinib in 2016 for the treatment of advanced RCC in patients who had received prior VEGFR inhibitor therapy.61
Two other large clinical trials explored VEGFR inhibitors in patients with advanced, nonmetastatic RCC who are at high risk of recurrence after surgery. Up to 40% of patients with stage III RCC experience a relapse with metastasis after kidney cancer surgery.62 There is currently no standard treatment for such patients, and the standard of care after surgery is surveillance.
In the S-TRAC (Sunitinib Treatment of Renal Adjuvant Cancer) trial, patients with stage III clear cell RCC were randomly assigned to treatment with sunitinib or placebo after surgery to remove the tumor.63 Sunitinib blocks VEGFR and several other molecular targets. The period until the cancer worsened was significantly longer in the sunitinib group (median, 6.8 years) than in the placebo group (median, 5.6 years). The rate of severe adverse effects, such as skin rash, high blood pressure, and fatigue, was higher in the sunitinib group than in the placebo group (63% v. 22%). Although these findings are encouraging, longer follow-up is needed to determine whether treatment with sunitinib in this setting prolongs survival.
In contrast, a much larger clinical trial, ASSURE (Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma; ECOG-ACRIN E2805), found no significant difference in the duration of disease-free survival between patients who received placebo (median, 6.6 years), sunitinib (median, 5.8 years), or sorafenib (median, 6.1 years) after surgery (this study was funded in part by a grant from the NCI).64 The most common severe adverse effects in the sunitinib and sorafenib groups were high blood pressure, hand-foot reaction, rash, and fatigue. Five deaths related to treatment occurred: one in the sorafenib group and four in the sunitinib group. The study authors concluded that neither sunitinib nor sorafenib should be used as adjuvant treatment for high-risk, advanced RCC.
Adjuvant VEGFR inhibitors should not be administered in the clinic until additional data are available to reconcile the differing results from the S-TRAC and ASSURE trials. A more compelling signal would be a trend toward survival benefit in either study, which currently does not exist. With multiple other adjuvant VEGFR studies underway, more data should be available to adjudicate the role of this treatment strategy. Physicians should continue to encourage enrollment of patients in ongoing trials that further explore the question.
A Policy Focus: Efforts Continue to Expand Access to Clinical Trials
ASCO continues to be concerned that only 3% of adult patients with cancer participate in clinical trials.1 This low participation rate not only limits patient access to new interventions that could treat, or even cure, their cancer, but also limits the knowledge gained from scientific inquiry to a small subset of patients.
ASCO submitted comments to the US Department of Health and Human Services and the National Institutes of Health on proposed rules aimed at increasing clinical trial participation and making clinical trial data more accessible and useful. The final rule, released in September 2016, requires researchers to register trials so that patients and their health care providers can more easily access trial information and determine if a patient is eligible to participate. In addition, researchers must also provide more detailed trial summary results, including information on adverse health events, on ClinicalTrials.gov.
Although this is a major step forward, more work is needed to expand access to clinical trials. Patients with low socioeconomic status, older adults, and ethnic and racial minority groups are under-represented in clinical trials. This impedes our ability to make progress against cancer in the populations who experience disparities in access to cancer care and treatment outcomes. ASCO continues to work with policymakers to expand access to clinical trials by relaxing overly restrictive eligibility requirements and by requiring Medicaid to cover routine costs of care for clinical trial participants. ASCO also worked with the American Association of Cancer Institutes through the Best Practices in Cancer Clinical Trials Initiative to develop and promote practical solutions to meet administrative and regulatory requirements in clinical cancer research.
1 Institute of Medicine Forum on Drug Discovery, Development, and Translation: Transforming Clinical Research in the United States: Challenges and Opportunities: Workshop Summary. Washington, DC, National Academies Press, 2010
Promising treatment for ovarian cancer.
With survival in the range of 12 to 18 months, women with recurrent ovarian cancer are in desperate need of better therapies. Research findings reported in 2016 may lead to a new approach to treat this difficult cancer.65 In an early-stage clinical trial, four of 10 women with folate receptor alpha–positive ovarian cancer resistant to standard platinum chemotherapy experienced tumor shrinkage after receiving IMGN853 (mirvetuximab soravtansine). The most common adverse effects were diarrhea, eye problems, cough, fatigue, and decreased appetite.
IMGN853 belongs to the new class of cancer therapies known as ADCs. It comprises an antibody targeting folate receptor alpha (a marker found in most ovarian cancers) and a potent anticancer drug called DM4, which blocks cell division and growth. Additional clinical trials of IMGN853 in women with folate receptor alpha–positive ovarian cancer are already underway (ClinicalTrials.gov identifiers: NCT02631876 and NCT02606305).
Combined Modality Therapy
It is common that patients with cancer receive two or more treatments at a time, at least at some point during the course of their illness. Such common modality therapies can work better than standalone treatments, but this improved efficacy often comes with more adverse effects. As with all new approaches, before any new combination of treatments becomes part of routine care, its benefits and safety need to be evaluated in a clinical trial against a standard treatment regimen. Last year, clinical trials delivered important advances in combined modality therapies for brain cancer, neuroblastoma, and colorectal cancer.
Adding chemotherapy to radiation therapy extends glioma survival.
In 2016, scientists reported long-awaited results from a federally funded clinical trial of patients with grade 2 glioma (this study was funded by a grant from the NCI).66 Grade 2 gliomas are rare, accounting for only 5% to 10% of all brain tumors, and often occur in younger people. Although low-grade gliomas grow slower than other types of brain cancer, they lead to worsening neurologic symptoms and often premature death.
In the study, patients were randomly assigned to receive radiation therapy alone or radiation therapy followed by PCV (procarbazine, CCNU, and vincristine) chemotherapy. The median survival was substantially longer among patients treated with chemotherapy and radiation therapy (13.3 years) than among those who received radiation therapy alone (7.8 years). Addition of chemotherapy also slowed the course of the disease; at 10 years, the cancer worsened in only 21% of patients in this group. In contrast, cancer worsened in 51% of patients treated with radiation therapy alone. This study led to a change in the standard of care for high-risk, low-grade gliomas; PCV chemotherapy is now added to radiation therapy.
More effective regimen for children with high-risk neuroblastoma.
Neuroblastoma is the second most common solid tumor in children and the most common cancer in infancy. It begins in nerve cells outside of the brain. Approximately 700 children are diagnosed with neuroblastoma each year in the United States, most younger than age 6 years. High-risk neuroblastoma requires intensive treatment, which may include surgery, chemotherapy, radiation therapy, and/or autologous stem cell transplant (ASCT). Despite all these treatments, fewer than half of children will survive 5 years after diagnosis of a high-risk neuroblastoma.
A federally funded trial performed by the Children's Oncology Group found that adding a second autologous stem cell transplant or ASCT to standard therapy can improve patient outcomes (this study was funded in part by a grant from the NCI).67 At 3 years, cancer had not recurred in 61% of patients who had undergone two transplantations, compared with 48% of patients who had undergone one.
The 3-year survival rate was slightly higher in the double transplantation group than in the single transplantation group (74% v. 69%), but this difference was not statistically significant. This study was not designed to observe a difference in overall survival between the two treatment groups. However, given that most neuroblastoma recurrences occur within 2 to 3 years of diagnosis, patients who had not experienced a recurrence at 3 years had a better chance of long-term survival.
The rates of severe adverse effects, such as infections and liver problems, were similar between the two treatment groups, although fewer treatment-related deaths occurred with double transplantation. Nonetheless, it is important to keep in mind that the combination therapy for high-risk neuroblastoma is one of the most aggressive cancer regimens administered to children. Longer patient follow-up is needed to determine if there are any long-term or late-onset adverse effects of this therapy.
Colon tumor location: a factor to consider in treatment decisions.
An unexpected factor may help explain why some patients with colorectal cancer do better than others. According to an analysis of data from a large clinical trial, patients with advanced colorectal cancer live longer if the cancer begins on the left side of the colon rather than on the right side (this study was funded in part by a grant from the NCI).68 In the trial, patients received a combination of FOLFOX (fluorouracil, leucovorin, and oxaliplatin) or FOLFIRI (fluorouracil, leucovorin, and irinotecan) chemotherapy with either of the two standard targeted therapies for advanced colorectal cancer: cetuximab or bevacizumab. In prior research, the two treatments yielded similar survival. In this analysis, the median survival for patients with left-sided tumors was 33 months, but it was only 19 months for those with right-sided tumors.
A separate analysis of data from two other clinical trials also found that patients with advanced colorectal cancer that began on the left side of the colon lived longer than those with cancers that began on the right side.69 Among patients with left-sided tumors, the combination of cetuximab and FOLFIRI was more effective than bevacizumab and FOLFIRI, whereas patients with right-sided tumors experienced limited benefit from either regimen.
For now, the compelling findings from these studies suggest that clinicians should take into account the location of the primary tumor when making treatment decisions for patients with advanced colorectal cancer. For patients with a right-sided colorectal cancer, cetuximab may not provide a benefit. However, for those patients whose tumors originate in the left colon, either a bevacizumab- or cetuximab-based regimen is effective, with cetuximab seeming to produce the best outcomes when combined with chemotherapy.
Finally, an analysis of pooled data from 66 clinical trials and more than 1.4 million patients revealed that left-sided primary colon tumors were associated with a better prognosis than right-sided tumors, irrespective of cancer stage.70 Overall, patients with left-sided tumors had a 20% lower risk of death. This analysis suggests that the location of primary tumor should be considered when establishing prognosis and designing future clinical trials in both early and advanced colorectal cancers.
Even in the era of precision medicine, chemotherapy remains a key treatment modality for many patients with cancer. Along with development of new chemotherapies, researchers are exploring new ways to use conventional chemotherapies. The past year brought important advances in chemotherapy for treatment of patients with pancreatic cancer and leukemia.
Pancreatic cancer: two-drug regimen increases chance of living longer.
Pancreatic cancer is often difficult to diagnose. As a result, it is often not found until it has spread from the pancreas to other parts of the body and can no longer be removed with surgery. Overall, only 29% of patients with pancreatic cancer will be alive 1 year after diagnosis. As the fourth leading cause of death resulting from cancer in the United States, pancreatic cancer took an estimated 42,000 lives in 2016.71
Patients who are diagnosed early enough for surgical removal of the tumor have a chance of longer survival. For the past two decades, the standard of care after pancreatic cancer surgery has been gemcitabine chemotherapy, which is administered to eliminate remaining cancer cells and reduce the chance of relapse. However, the benefit of gemcitabine is relatively modest, with only 20% of patients surviving 5 years.
A recent clinical trial found that adding a second chemotherapy drug, capecitabine, to gemcitabine can help such patients live even longer.72 The median survival was 28 months in the group of patients treated with the two-drug regimen and 25.5 months in the group that received gemcitabine alone. Despite a small difference in median survival, addition of capecitabine increased the chance of surviving 5 years from 16% to 29%.
These results have set a new standard of care for use of gemcitabine plus capecitabine as adjuvant (postsurgery) therapy after pancreatic cancer surgery. Gemcitabine and capecitabine are both FDA approved for use in several different cancers and are available as generic medicines.
The combination regimen was well tolerated overall, with no significant increase in adverse effects compared with gemcitabine alone. The safety of the gemcitabine–capecitabine combination allows for the possibility of adding other treatments to this regimen with the goal of further improving patient benefit.
High-risk AML: new packaging of conventional drugs extends survival.
With current therapy, people with AML live only approximately 6 months after diagnosis. There has been little improvement in AML survival in the last few decades, but last year brought not only a promising new targeted therapy (described under Targeted Therapy), but also an improved chemotherapy regimen.73
The new medicine, called CPX-351, packs cytarabine and daunorubicin into a liposome, which helps the chemotherapy slip into leukemia cells. CPX-351 was investigated in a late-stage clinical trial of older patients newly diagnosed with secondary AML. Secondary AML can develop as a result of treatment of another cancer or environmental exposure to radiation or certain chemicals.
In the study, patients who received CPX-351 lived approximately 4 months longer (median survival, 10 months) than those who received standard combination chemotherapy (median survival, 6 months) with the same drugs. At 2 years, 31% of patients were alive in the CPX-351 group versus 12% of patients in the standard chemotherapy group. There were no differences in adverse effects between the two groups of patients.
These findings represent a long-awaited advance in treatment of older adults with high-risk or secondary AML. The FDA has granted CPX-351 a breakthrough therapy designation for treatment of patients with AML.
New Concerns About Laparoscopic Rectal Cancer Surgery
In recent years, laparoscopic surgery has emerged as an attractive alternative to the traditional open surgery because of its shorter recovery time and lower rate of complications. The procedure is performed with the aid of a video camera and instruments inserted through small incisions in the abdomen.
Patients with early and locally advanced rectal cancer can be cured with surgery, provided the tumor tissue is completely removed. However, the choice between open and laparoscopic surgery is not easy to make for such patients. Experts have raised concerns that laparoscopic surgery may not remove tumor tissue as completely as open surgery does. As a result, patients who undergo laparoscopic surgery may have a greater chance of cancer recurrence and consequently shorter survival.
In one recent clinical trial, rates of surgical success (i.e., complete tumor removal) were found to be substantially lower among patients with rectal cancer who underwent laparoscopic surgery than among those who underwent open surgery (82% v. 87%).74 Similar trends were seen in another large trial, where successful surgery was achieved in 82% of patients undergoing a laparoscopic procedure and 89% of patients undergoing open surgery.75
These findings confirm concerns that laparoscopic surgery may lead to more cancer recurrences and shorter survival. Patients enrolled in these two trials will continue to be observed to answer this question. Meanwhile, routine use of laparoscopic surgery is not recommended for patients with stage II or III rectal cancer. In contrast, laparoscopic surgery is a well-accepted procedure for patients with colon cancer.
A Policy Focus: Robust Federal Funding Needed for Cancer Research Progress
ASCO continues to urge legislators to make a robust national investment in medical research through the National Institutes of Health (NIH) and the National Cancer Institute.
For much of the past decade, federal funding for biomedical research has been flat, and in inflation-adjusted dollars, the NIH budget was 20% lower in 2016 than it was a decade before.1 This dramatic drop in funding limits the ability of scientists to conduct important research that advances the prevention, diagnosis, and treatment of cancer for millions of people.
Even under tight budgetary constraints, Congress must provide consistent and predictable funding increases to continue our momentum to prevent cancer and improve cancer treatment for patients.
1 National Institutes of Health: Appropriations.
Longer Hormone Therapy Further Reduces Breast Cancer Recurrence
Breast cancer can recur many years after a woman completes treatment for early-stage, hormone receptor–positive breast cancer. To lower the chance of recurrence, many women receive hormone therapy after surgery. In 2016, researchers reported that extending a form of hormone therapy called aromatase inhibitors from the standard 5 years to 10 years may further reduce the risk of recurrence.76
The study enrolled postmenopausal women with early breast cancer who had completed 5 years of aromatase inhibitor hormone therapy either as first-line treatment or after tamoxifen. The women were randomly assigned to receive the aromatase inhibitor letrozole for 5 additional years or placebo.
The chance of breast cancer recurrence or development of a second cancer in the opposite breast was 34% lower in the letrozole group than in the placebo group. At 5 years of follow-up, 95% of women in the letrozole group and 91% of women in the placebo group remained breast cancer free. The rates of second breast cancers were lower in the letrozole group (0.2% v. 0.5%). Nonetheless, 5-year survival rates were not significantly different between the two groups (letrozole, 94% v. placebo, 93%).
Adverse effects of hormone therapy can be difficult to bear, particularly over a long period of time. Although bone pain, fractures, and osteoporosis occurred more frequently with letrozole than with placebo, researchers found no significant differences in either overall quality of life or menopause-specific symptoms.
Furthermore, a separate analysis of more than 45,000 patients who were observed for 15 years after receiving 5 years of hormone therapy provides a more accurate estimate of the risk of breast cancer recurrence according to initial tumor stage, grade, and lymph node status.77 The findings will help inform decisions about continuing hormone therapy beyond 5 years.
These findings are important to millions of women around the world who receive a diagnosis of hormone receptor–positive breast cancer each year. They provide much-needed direction to physicians and patients discussing whether to extend hormone therapy beyond the previous standard of 5 years, particularly in women who found the first 5 years of treatment acceptable.
Recent Clinical Practice Guidelines
Clinical practice guidelines help distill knowledge about a particular clinical issue and provide recommendations to help clinicians deliver the best treatment and care to every patient. ASCO develops its clinical practice guidelines through a rigorous, systematic review of relevant medical literature and clinical interpretation from a multidisciplinary panel of experts and patient representatives. In 2016, ASCO issued more than 17 new clinical practice guidelines, updates, adaptations, and endorsements (Appendix, Table A2).
For additional notable advances in cancer treatment, please see Appendix Table A1.


text:
Singapore Uniquely Singapore Websites Blogs The Chosen Glutton
(No Rating Yet)
The Chosen Glutton
Email Website Facebook Page 998 1 0
Write Review
Listing created by Ethan Wong on October 09, 2013
The Chosen Glutton is run by Edsmond, who gives brutally honest reviews on cafes/restaurant - good or bad. His blog was a best food blog finalist at the recent Singapore blog awards.
User reviews
Already have an account? Log in now or Create an account
User Ratings Summary
There are no user reviews for this listing.


text:
|Page (1) of 1 - 11/14/11
|email article
|print page
Hey Everyone I am Diana Madison For Hollyscoop! Say it isn't so that one of the hottest men in Hollywood will be retiring from showing off his hot face and body! In an interview 47-year-old Brad Pitt says he wants to retire at age 50. For someone w...
Source:GrabNetworks (c). All Rights Reserved


text:
My Trackers
my Nutrition
my Fitness
my Weight
Other Goals
my SparkPoints
Community Home
Community Feed
Message Boards
Challenge Central
Member Blogs
What's New
Health & Wellness
Weight Loss
Stuff We Love
Healthy Family
Pregnancy & Postpartum
Instant Inspiration
Food Database
Lifestyle Centers
The SparkPeople Blog
Stream hundreds of free workout videos and track them in one click. Get fit at home, at work or wherever you are!
Today's Featured Video:
Visit SparkPeople.TV
Access hundreds of thousands of recipes that are healthy and easy to make. Get full nutrition info for every recipe and track with one click!
Today's Featured Recipe:
Light Lemon Blueberry Donuts
Visit SparkRecipes.com
Accepting Donations!!
Friday, April 03, 2009
I have got to get this medical alert dog...it's getting crazy!! My sugar was 36 or lower when I was driving at lunch yesterday. I ran a red light, fortunately no accident occurred...but what about next time? I can not have this happening. I felt fine, I thought I could think fine and had no idea there was anything wrong, until I saw the light was red...AS I WAS DRIVING THROUGH IT, then as I drove on through, I noticed that I had no idea where I was. I had missed my turn. This was way beyond dangerous. Not just for me but for everyone else who happened to be on the road with me that afternoon. I could have killed people if I had caused an accident.
The bad thing is that the only place I can get a dog from says it will cost AT LEAST $7500 to get one and pay for all the classes etc. That is about 1/3 my yearly salary. I can't just fork that over. So, I am going to have to rely on donations and whatever else I can get.
I was told to try putting an add in the paper. I don't exactly know what that would mean, but I'm thinking it's worth a try. Maybe my local television station Channel 7 could run a story on the home page of their website. Something getting the word out, that I need help!!
So, I am going to rely on what ever help I can get. If you can help me or know an organization that might be able to help please get in touch with me.
The good thing about this is that I not only get the dog for myself but I will gain the skills to train other dogs. I plan on using what I learn to open up a non profit dog training place for the state of Oklahoma and surrounding areas. So, with this I will be able to help other Oklahomans and people from other neighboring states who need the help, and like me are unable to afford it themselves. Though, I would do my best not to charge nearly the amount this place charges, and I would not use private dog breeders. I would breed my own dogs and train them.
So, if this sounds like something good, please help me in any way that you can. Together we can change the world as far as other diabetics. Plus, you just might save my life, and the lives of so many others!!
Please...I beg of you!!
Share This Post With Others
Report Inappropriate Blog
Member Comments About This Blog Post
Be the First to Add Your Comment to the Blog Post
Log in to post a comment
Disclaimer: Weight loss results will vary from person to person. No individual result should be seen as a typical result of following the SparkPeople program.
Get An Email Alert Each Time
REDEYE.TREEFROG Posts
See Today's Featured Member Blog Posts
More Blogs by REDEYE.TREEFROG
It's been a while
- 4/9/2009
First Cardio, and the effects after wards:
- 3/30/2009
This coming weekend
- 3/26/2009
Stage 2
- 3/25/2009
View All ›
close ×


text: Dominant Traits-In genetics, a trait that will appear in the offspring if one of the parents contributes it. Recessive Traits-Recessive Traits can be carried in a person's genes without appearing in that person. Phenotype Traits-A phenotypic trait is an obvious and observable trait; it is the expression of genes in an observable way. Genotype Traits-there are underlying genes that control the hair color, which make up the genotype, but the actual hair color, the part we see, is the phenotype.


text:
Overdrive Pedals
Mad Professor Sweet Honey Overdrive Deluxe$189.95The sweetest overdrive in the land just got a little sweeter. Learn More
Mad Professor Little Green Wonder CB$169.00The Mad Professor Little Green Wonder CB is a foundation overdrive with a unique lower-mid frequency bump control. Now available in a Printed Circuit board format with all the same attention to detail present in the hand-wired version. Learn More
Mad Professor Royal Blue Overdrive CB$169.95
Dress your tone up in some touch-sensitive amp-like royalty courtesy of the Mad Professor Royal Blue Overdrive.Learn More
Mad Professor Ruby Red Booster CB$169.00The Mad Professor Ruby Red Booster CB is a treble boost and clean boost in one sweet little box. With the Mad Professor Ruby Red Booster CB you can use any combination of treble boost, clean boost or overdrive. Learn More
Mad Professor Simble Predriver$169.00If you've ever played a Simble, you know that it's a box rich in tone. It's not just a boost, it's a preamp with several tuneful qualities, such as compression and harmonic enhancement. Learn More
Mad Professor Simble Overdrive$189.00The Simble bridges the gap between you and the 40,000-dollar amp of your dreams. The next step toward tonal finality has arrived. Learn More
Mad Professor Amber Overdrive CB$169.95The Mad Professor Amber Overdrive is a gem that brings thick, thunderous overdrive with a hint of fuzz to even the cleanest amp. Learn More
Mad Professor Sweet Honey Overdrive CB$169.00The Mad Professor Sweet Honey Overdrive CB is the circuit board version of Mad Professor's classic low gain touch sensitive overdrive. The Mad Professor Sweet Honey Overdrive CB has the same circuits and components as the classic Sweet Honey OD. Learn More
Mad Professor Big Tweedy$195.95When it comes to tweed amp-in-a-box tones, it's time to go Big or go home. Learn More
Magnetic Effects Sändare$145.00
The drive pedal for those of you who swore you'd never use pedals.Learn More
McCaffrey Audio Zero to Sixty Drive$169.00Like many other pedalbuilders, Ryan McCaffrey got his start by modding existing pedals to meet his and his customers' exact needs. Soon enough, existing topology just wasn't cutting it, and after more and more tinkering and experimentation, the Zero to Sixty drive was born. Learn More
ModTone Dirty Duo$119.99The Modtone DirtyDuo certainly lives up to its name—players get two top-shelf overdrives in one box. And it's not two effects in one, it's quite literally two stackable overdrives that can be used separately. Learn More
Moog MF Drive - Minifooger Series$169.00The MF Drive is a unique, filter-based overdrive pedal that employs a Moog Ladder Filter, boutique FET amplifiers, and classic OTAs in its drive section making it highly reactive to input gain and picking dynamics. Learn More
Mr. Black JDS-50 Overdrive$179.95The JDS-50 is an original design that steps up to the overdrive plate and crushes it out of the park. Learn More
MXR M250 Double-Double Overdrive$129.99
MXR's Double Double marries two classic drive circuits in one compact box.Learn More
MXR M264 FET Driver$149.99The FET Driver thickens up lead tones with musical, amp-like distortion and sustain without the fragility and inconsistency associated with tubes. Learn More
MXR M89 Bass Overdrive$129.99The MXR M89 Bass Overdrive is a unique, harmonically rich overdrive circuit designed especially for bass. The Clean knob allows you to blend in a tuned clean signal to give your tone remarkable clarity and definition. Learn More
MXR Custom Shop Il Torino Overdrive CSP033$119.99Designed entirely by Carlo Sorasio, owner and engineer of Laa-Custom, an amp and effects company. With so much attention to detail going into the Laa-Custom catalog, a collaboration with MXR can only mean good things. Well, they nailed it. Learn More
MXR CSP036 Il Diavolo B-Stock
Regular Price: $129.99
Special Price: $103.99
MXR has partnered up with Carlo Sorasio of LAA Custom for a new breed of drive.Learn More
MXR EVH 5150 Overdrive$199.99It's here: THE definitive EVH overdrive, courtesy of Dunlop. The 5150 Overdrive was developed by Dunlop engineer Bob Cedro in conjunction with Eddie himself. It pretty much nails Eddie's tone, and this isn't hyperbole—Eddie himself agrees. Learn More


text:
Britain's bestselling SF writer returns to outer space.In AD 2329, humanity has colonised over four hundred planets, all of them interlinked by wormholes. With Earth at its centre, the Intersolar Commonwealth now occupies a sphere of space approximately four hundred light years across.When an astronomer on the outermost world of Gralmond, observes a star 2000 light years distant - and then a neighbouring one - vanish, it is time for the Commonwealth to discover what happened to them.
There are no reviews for this title yet.
The year is 2380. The Intersolar Commonwealth, a sphere of stars some 400 light-years in diameter, contains more than 600 worlds, interconnected by a web of transport "tunnels" known as wormholes. At the farthest edge of the Commonwealth, astronomer Dudley Bose observes the impossible: Over 1,000 light-years away, a star...vanishes. It does not go supernova. It does not collapse into a black hole. It simply disappears.
The high-action concluding novel of the Commonwealth Saga from one of the world's bestselling Science Fiction writersAfter hundreds of years secretly manipulating the human race, the Starflyer alien has succeeded in engineering a war which should result in the destruction of the Intersolar Commonwealth.
Robust, peaceful, and confident, the Commonwealth dispatched a ship to investigate the mystery of a disappearing star, only to inadvertently unleash a predatory alien species that turned on its liberators, striking hard, fast, and utterly without mercy.The Prime are the Commonwealth's worst nightmare. Coexistence is impossible with the technologically advanced aliens, who are genetically hardwired to exterminate all other forms of life.
It's 2040. After decades of research, scientists of the European Union believe that they have at last conquered humankind's most pernicious foe: old age. For the first time, technology holds out the promise of not merely slowing the aging process but actually reversing it. The first subject for treatment is 78-year-old philanthropist Jeff Baker. After 18 months in a rejuvenation tank, Jeff emerges looking like a 20-year-old. And the change is more than skin deep. From his hair cells down to his DNA, Jeff is 20 - with a breadth of life experience.


text:
Australian Tattoo Facts & Statistics
Who has tattoos in Australia? At what age do Australians get their first tattoo? How many tattoos do Australians have? Here are the answers, and other interesting Australian tattoo statistics for males and females.
Infographic Source: Disappear Ink Tattoo Removal Clinic
Embed This Image On Your Site (copy code below):


text:
"Fantastic Service"
About: Trafford General Hospital Trafford General Hospital M41 5SL
Posted by Anonymous
What an invaluable service. My daughter was ill over the weekend and we took her to the walk-in centre where she was immediately prescribed anti-biotics. If we had waited to see our GP, she may not have received a prescription for a couple of days.
Response from Central Manchester University Hospitals NHS Foundation Trust 2 years ago
Thank you for taking the time to provide your feedback on the service you received at the Trafford Walk-in-Centre.
We are extremely pleased to hear that you had a positive experience and received timely treatment for your daughter.
We will ensure that your kind comments are passed to staff at the Walk-in-Centre which will be a valued moral boost for all.
Thank you again for providing your feedback, we really appreciate and value your input'
The Patient Experience Team
Central Manchester University Hospitals NHS Foundation Trust
- {{helpful}} of {{total()}} people think this response is helpful
- Was this response helpful? Yes | No
Thank you for your feedback.
See more responses from Central Manchester University Hospitals NHS Foundation Trust


text: Bratz Rodeo. "How the West is Worn! Kick up your heels 'cuz the Bratz are goin' west and gettin' wild in designer duds so rip-roarin' and hip-huggin' they oughta be outlawed!" - this is the same description from the Wild Wild West and Wanted collections. Rodeo included Cloe, Sorya and Yasmin. Dolls came with the star brush.


text:
The Iraqi army on Saturday called on residents of Qayyara, a town held by Islamic State, to leave ahead of a military operation aimed at recapturing the strategic town from the extremist militia.
Qayyara is located around 60 kilometres south of Mosul, which is Islamic State's stronghold in northern Iraq.
"Our brave troops have encircled the Daeshis and it remains for them to receive orders to storm Qayyara," the Iraqi Defence Ministry said, using an Arabic acronym for Islamic State militants.
The ministry added in a statement that the town's inhabitants must leave "immediately" for safety and head to a nearby government-controlled village and the air base of Qayyara.
Some 79,000 people are believed to have lived in Qayyara before Islamic State seized it in June 2014.
Last month, Iraqi government forces, backed by US-led airstrikes, retook control of the air base of Qayyara from Islamic State.
The facility is located around 50 kilometres south of Mosul, Iraq's second-largest city, which has been under Islamic State control since mid-2014.
Prime Minister Haider al-Abadi has repeatedly vowed to retake Mosul from Islamic State, which has in recent months suffered several military setbacks and lost ground in Iraq and neighbouring Syria.


text:
WASHINGTON (Reuters) - The head of the International Monetary Fund on Thursday warned that the fight over raising the U.S. government's debt ceiling could be "catastrophic" for the global economy if not resolved in time.
"If it is not resolved appropriately by it being raised on time ... it could be catastrophic for the global economy," IMF Managing Director Christine Lagarde told Reuters Insider television.
"I very, very strongly hope that all parties, all views will converge in the national interest of the U.S. economy and in the international interest of the global economy. To imagine that the U.S. economy would be in default, would not honor the payments that it owes is just unthinkable."
Reporting by Timothy Ahmann; Editing by Chizu Nomiyama


text:
Three is never a crowd with this tantalising toy!
The very first vibrator designed for use during sex play itself, it can also be used alone for supreme satisfaction every time. Stimulating the clitoris and g-spot simultaneously, it also promises your playmate really good vibes should you choose to include them. Perfectly contoured to hit the 'spot', it boasts 2 powerful motors and six vibration modes for sensational squirting. Plus, now you can have gratification on the go, as this clever device is hands free and portable.
Crafted from fine quality materials, you can be sure that you're getting superior quality that's built to last with the We Vibe II. It even comes complete with a 1 year warranty.
This toy will give you a real buzz...
Delivery & Returns
Additional Information
|SKU / Product Code
|We Vibe


text:
We called this episode Training the twink and obviously Bobby Noiret qualifies as the twink in this partnership. It is in fact one of Bobby`s training scenes and luckily he got one of our most experienced performers to show him the ropes.
Gaelen Binoche, as always, is stunning and does his best to impart of his wealth of experience to young Bobby.
Length: 872 MiB Duration: 20mn 59s 839ms
Video: AVC at 5 668 Kbps, Aspect: 1440 x 810 (1.778) at 29.970 fps
Audio: AAC at 128 Kbps, Infos: 2 channels, 48.0 KHz
Download from: